Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
More News related to ABI
- Exploration Diamond Drilling to Start Soon on Abcourt's Elder and Tagami Gold Properties
- Exploration Diamond Drilling to Start Soon on Abcourt's Elder and Tagami Gold Properties
- Abcourt Mines Inc. Amends the Terms of the Warrants Issued in November 5, 2007
- Abcourt Mines Inc. Amends the Terms of the Warrants Issued in November 5, 2007
- Abcourt Grants Stock Options to a Director
More News related to ALO
- American Electric Power Awards Alstom Power Contracts Worth Over USD 100 Million (EUR70 Million) to Add Power and Reliability to Its DC Cook 1 and Conesville 4 Power Plants in the US
- Alstom and Schlumberger Seal a Joint Agreement to Develop Carbon Capture & Storage Readiness Studies For Power Plants
- Video: AEP and Alstom Commission First of Its Kind Carbon Capture and Sequestration (CCS) Project
- Pilot Project Captures 90% of CO2
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
More News related to BRL
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Top 15 For 2008 (No. 14): M&A Wreckage
- Teva Pharmaceutical (TEVA) and Bar Pharma (BRL) Receives Merger Approval From European Commission
More News related to Insiders' Blog
- Peet's (PEET) Moving Even Lower as Cowen Issues Mid-Day Downgrade
- RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
- BMO Capital Downgrades Terra Industries (TRA) to Market Perform
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Sterne Agee Downgrades Shoe Apparel Stores FINL & FL
Today, Astellas Pharma went hostile with its $16 per share bid for CV Therapeutics, Inc. (Nasdaq: CVTX) after CV rejecting the initial offer. The $16 offer represents a 41% premium yesterday's closing share price and a 69% premium to its 60-day average closing price. Are they crazy?
It appears CV Therapeutics forgot the lessons of recent merger-cockiness gone awry in the last year. Well here is a refresher course for them:
- Yahoo! (Nasdaq: YHOO) rejects $31 bid from Microsoft (Nasdaq: MSFT). Today's Price = $11.15
- Rio Tinto (NYSE: RTP) rejects takeover from BHP when stock was over $400 per share. Today's Price = $93
- Take-Two Interactive Software (NASDAQ: TTWO) rejects $26 offer from EA (Nasdaq: ERTS). Today's Price = $7.50
- SanDisk (Nasdaq: SNDK) rejected at $26 offer from Samsung. Today's Price = $12
- Heelys, Inc. (Nasdaq: HLYS) rejected a $5.25 shares offer from Skechers (NYSE: SKX). Today's Price = $2.00.
- Mentor Graphics (Nasdaq: MENT) rejected a $16 offer from Cadence Design (Nasdaq: CDNS). Today's Price = $5.
- Calpine Corp. (NYSE: CPN) rejcted $23 offer from NRG Energy, Inc. (NYSE: NRG). Today's price = $7.25
- Genentech Inc. (NYSE: DNA) rejected an $89 offer from Roche. Its stock has since dropped to $84.
So, based the data points above, it looks like they are crazy for not taking the deal.
But CV Therapeutics has one thing going for them. That thing is the sector that they play in - biotech.
Biotech has been one of the few sectors actually seeing deals, and the deals have been at nice premiums. Maybe CV belives they can hold on for more money from Astellas or another suitor.
Some notable deals in biotech/phama over the past year:
- Johnson & Johnson (NYSE: JNJ) bought Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) for approximately $438 million
- Sciele Pharma, Inc. (NASDAQ: SCRX) was bought for $1.1 billion
- Eli Lilly and Company (NYSE: LLY) bought ImClone Systems (Nasdaq: IMCL)
- Invitrogen Corporation (NASDAQ: IVGN) merger with Applera's Applied Biosystems Group (NYSE: ABI)
- Johnson & Johnson (NYSE: JNJ) bought Mentor Corp. (NYSE: MNT) for $1.07 billion
- King Pharmaceuticals, Inc. (NYSE: KG) bought Alpharma, Inc. (NYSE: ALO)
- Teva Pharmaceuticals (Nasdaq: TEVA) bought Barr Pharmaceuticals, Inc. (NYSE: BRL)
- Takeda Pharmaceutical agreed to acquire Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) for $8.8B
- Pfizer (NYSE: PFE) buys Wyeth (NYSE: WYE) in $68B deal
CV Therapeutics has not commented on the offer yet.
Related Categories
Insiders' BlogStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
